About ObsEva
ObsEva is a company based in Geneve (Switzerland) founded in 2012. ObsEva has raised $94.7 million across 6 funding rounds from investors including Merck, New Leaf Venture Partners and Orbimed. ObsEva operates in a competitive market with competitors including Sprout Pharmaceuticals, Hope Medicine, Rejoni, Gameto and Forendo Pharma, among others.
- Headquarter Geneve, Switzerland
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Obseva Sa
-
Annual Revenue
$19.64 M (USD)-12as on Dec 31, 2022
-
Net Profit
-$29.88 M (USD)44as on Dec 31, 2022
-
EBITDA
-$15.68 M (USD)72as on Dec 31, 2022
-
Total Equity Funding
$94.7 M (USD)
in 6 rounds
-
Latest Funding Round
-
Investors
Merck
& 15 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of ObsEva
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of ObsEva
ObsEva has successfully raised a total of $94.7M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Last Round
-
First Round
First Round
(29 Aug 2013)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Post-IPO - ObsEva | Valuation |
investors |
|
| Aug, 2019 | Amount | Debt – Conventional - ObsEva | Valuation |
investors |
|
| Oct, 2017 | Amount | Post-IPO - ObsEva | Valuation |
investors |
Investors in ObsEva
ObsEva has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, New Leaf Venture Partners and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Stage-agnostic investments in US life sciences are managed.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ObsEva
Financial Statements - ObsEva
Obseva Comparisons
Competitors of ObsEva
ObsEva operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sprout Pharmaceuticals, Hope Medicine, Rejoni, Gameto and Forendo Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drugs for hypoactive sexual desire disorder in women are developed.
|
|
| domain | founded_year | HQ Location |
Monoclonal antibodies are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for women's health conditions are developed using innovative hydrogels.
|
|
| domain | founded_year | HQ Location |
Therapeutics for fertility and menopause treatments are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for reproductive health are developed.
|
Latest news on Obseva
Frequently Asked Questions about ObsEva
ObsEva was founded in 2012 and raised its 1st funding round 1 year after it was founded.
ObsEva is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
ObsEva is a funded company, having raised a total of $94.7M across 6 funding rounds to date. The company's 1st funding round was a Post-IPO of $60M, raised on Aug 29, 2013.
Annual revenue of ObsEva is $19.64M as on Dec 31, 2022.
Developer of therapeutics for womens reproductive health and pregnancy. Its lead candidate is Linzagolix an orally active gonadotropin-releasing hormone and receptor antagonist for Fibroids and Endometriosis. It also has two receptor antagonists Ebopiprant and Nolasiban for preterm labor.
ObsEva's top competitors include Sprout Pharmaceuticals, Rejoni and Hope Medicine.
ObsEva has 16 investors. Key investors include Merck, New Leaf Venture Partners, Orbimed, Oxford Finance, and HBM Healthcare Investments.